Table 3.
Placebo group |
Oxytocin group |
Difference placebo versus oxytocin group |
|||||||
---|---|---|---|---|---|---|---|---|---|
Coordinates | t value | p value | Coordinates | t value | p value | Coordinates | t value | p value | |
Dorsal/Ext Amy | 22, −4, −10 | 3.26 | NS | 20, −2, −10 | 2.17 | NS | |||
R Insula | 40, 22, 2 | 4.18 | <0.001 | 34, 20, 2 | 3.29 | NS | |||
L Insula | −32, 20, 6 | 4.89 | <0.001 | ||||||
rACC/vmPFC | 12, 48, 18 | 4.20 | <0.001 | −8, 50, 6 | −3.49 | 0.001 | |||
dmPFC | |||||||||
mObfc | 20, 60, −4 | 4.74 | <0.001 | 18, 44, −16 | 3.42 | 0.001 | |||
lObfc | −30, 42, −12 | 3.39 | 0.001 | ||||||
lObfc | 28, 56, 8 | −3.46 | 0.001 | ||||||
vlPFC | 32, 60, 2 | 3.55 | <0.001 | −40, 36, 0 | −3.69 | 0.001 |
Dorsal Amy, Dorsal amygdala; Ext Amy, extended amygdala; rACC, rostral anterior cingulate cortex; vmPFC, ventromedial prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; mObfc, medial orbitofrontal cortex; lObfc, lateral orbitofrontal cortex; vlPFC, ventrolateral prefrontal cortex; R, right; L, left; NS, nonsignificant.